PNC Financial Services Group
VERV

PNC Financial Services Group’s Verve Therapeutics VERV Stock Holding History

PNC Financial Services Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-726
Closed -$8.15K – 5239
2025
Q2 		$8.15K Buy
726
+716
+7,160% +$4.08K ﹤0.01% 3952
2025
Q1 		$46 Sell
10
-32
-76% -$214 ﹤0.01% 4844
2024
Q4 		$237 Buy
+42
New +$237 ﹤0.01% 4634
2024
Q2 		– Sell
-2,073
Closed -$27.5K – 4923
2024
Q1 		$27.5K Sell
2,073
-21
-1% -$278 ﹤0.01% 3274
2023
Q4 		$29.2K Buy
+2,094
New +$26K ﹤0.01% 3232
2022
Q1 		– Sell
-2
Closed – – 4710
2021
Q4 		$0 Buy
+2
New +$84 ﹤0.01% 4622

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

PNC Financial Services Group's VERV Position: Q3 2025 in Review

PNC Financial Services Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 726 shares — an estimated $8.15K sold.

PNC Financial Services Group first reported a position in VERV in Q4 2021 and held it in 6 quarters. The position peaked at $29.2K in Q4 2023. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • PNC Financial Services Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 726 Verve Therapeutics shares in Q3 2025, an estimated $8.15K.
  • PNC Financial Services Group first reported a position in Verve Therapeutics in Q4 2021 and held it in 6 quarters.
  • PNC Financial Services Group's Verve Therapeutics position peaked at $29.2K in Q4 2023.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.